Different interpretations of the CheckMate-227 trial in non-small-cell lung cancer

Benzer Materyaller

• From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
  Yazar:: Deng, Haiyi, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
  Yazar:: Horn, Leora, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
  Yazar:: Owonikoko, Taofeek K., ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
  Yazar:: Waterhouse, David M., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
  Yazar:: Borghaei, Hossein, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)